Sign in
Taking people in NetherlandsPhase 1

E-VIM Vaccine CVX1 With or Without Immunotherapy for Bladder or Kidney Cancer

Tests the E-VIM vaccine CVX1 in adults with bladder or kidney cancer.

Key facts

Who runs it
CimCure B.V.
Where
Amsterdam, Leiden, and Rotterdam, NetherlandsSee the 4 sites
Registry title
PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).
Status
Recruiting
Phase
Phase 1
People taking part
83 people, planned
Started
2 Apr 2026
Expected to end
31 Mar 2029
Type of study
Interventional
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with muscle invasive bladder cancer or localized or locally advanced kidney cancer (renal cell cancer). It tests the safety of the E-VIM vaccine CVX1, with or without an immune checkpoint inhibitor (ICI).

Age
18 years or older
Sex
All sexes can join
Disease stage
Muscle invasive bladder cancer, or localized or locally advanced renal cell cancer (RCC)

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
  • Netherlands Cancer InstituteAmsterdam, NetherlandsTaking people
  • Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
E-VIM Vaccine CVX1 With or Without Immunotherapy for Bladder or Kidney CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
14 September 2026